[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
March 15, 2006

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients—Correction

JAMA. 2006;295(11):1252. doi:10.1001/jama.295.11.1252

Failure to Disclose Financial Interest: In the Original Contribution entitled “Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial” published in the February 15, 2006, issue of JAMA (2006;295:761-775), the following financial disclosure should be added for Julio Rosenstock, MD. On page 774, under “Financial Disclosures,” “Dr Rosenstock has received honoraria from Sanofi-Aventis for lectures and for consultant services” should be added right before “No other authors reported financial disclosures.”

×